**AUB KQ1 Evidence Table (Reference ID #1777)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality****Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**Oner and Muderris, 2011**Country:**Turkey**Enrollment period:** March 2008 to April 2009**Intervention setting:** University gynecologic endocrinology clinic**Funding:**NR**Author industry relationship disclosures:**NR**Study Design:** RCT**Blinding:** NR | **Intervention:**1.5 g/day metformin (500 mg 3 times per day)**Comparator:**1.8 g/day N-acetyl-cysteine (600 mg 3 times per day)**Groups:****G1:** Metformin**G2:** N-acetyl-cysteine **Followup:**24 weeks | **Inclusion criteria:** PCOSa with hirsutism and menstrual irregularity**Exclusion criteria:** Congenital adrenal hyperplasia, Cushing’s syndrome or androgen secreting tumors, thyroid disease, hyperprolactinemiaDiabetes mellitus or impaired glucose tolerance Use of drugs known to affect carbohydrate metabolism within 3 months preceding the study**N at enrollment:** **G1:** 50**G2:** 50**N at followup:** **G1:** 30**G2:** 45**Age, mean years ± SD:****G1:** 22.6 ± 4.8**G2:** 23.7 ± 4.4**BMI, mean kg/m2 ± SD:****G1:** 24.3 ± 6.2**G2:** 23.0 ± 4.6**Parity:**NR**Race/ethnicity:**NR | **Menstrual cycle:**Regular, n (%):**G1:** 5 (17)**G2:** 13 (29)**G1 vs. G2:** p=NSIrregular, n (%):**G1:** 25 (83)**G2:** 32 (71)**G1 vs. G2:** p=NS | **Menstrual cycle:**Regular, n (%):**G1:** 14 (47)**G2:** 24 (53)**G1 vs. G2:** p=NSIrregular, n (%):**G1:** 16 (53)**G2:** 21 (47)**G1 vs. G2:** p=NSRestoration of menstrual regularity, n (%):**G1:** 9 (36)**G2:** 11 (34)**G1 vs. G2:** p=NS**Quality of life:**NR**Pain:**NR**Sexual function:**NR**Patient satisfaction:**NR**Fertility:**NR**Time to conception:**NR**Additional interventions:**NR**Adverse Events:**Discontinued due to gastrointestinal side effects, n (%):**G1:** 2 (4)**G2:** NR | **Overall quality:**Poor**Risk of bias:**Randomization:UnclearAllocation concealment:UnclearSelective reporting:LowBlinding patients/personnel:UnclearBlinding outcome assessment:UnclearIncomplete outcome reporting:HighOther:Unclear |

**Table Notes:** a PCOS defined as presence of at least two of following three criteria: (1) oligo- or anovulation, (2) clinical and/or chemical signs of hyperandrogenism and/or (3) polycystic ovaries.